Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Recharged hopes of Brexit deal, trade truce power UK shares

Thu, 10th Oct 2019 09:40

* FTSE 100, FTSE 250 up 0.3%

* Mondi reverses course to close higher

* Miners biggest boost to main index

* FTSE 100 confirms "Death Cross" pattern
(Adds company news items, updates share moves, changes analyst
comments)

By Muvija M and Shashwat Awasthi

Oct 10 (Reuters) - London stocks finished a roller coaster
session on Thursday with gains as domestic companies rose after
Britain and Ireland said they saw a pathway to a Brexit deal,
and international names jumped on to a global rally over hopes
of a U.S.-China trade truce.

The FTSE 100 ended 0.3% higher, after flipping back
and forth during the day on mixed signals over the state of
affairs between Beijing and Washington, while the midcap index
that has a greater UK exposure also rose by the same level.

However, a more than 1% surge in sterling on renewed
prospects of a Brexit agreement kept a lid on gains for the
blue-chip bourse, which earns a sizeable portion of its earnings
in the U.S. dollar.

Spirits company Diageo, consumer goods giant
Unilever and AstraZeneca were among stocks
hammered the most, causing the FTSE 100 to lag other major
indexes.

Stocks vulnerable to a hit from Brexit, on the other hand,
overpowered those losses. Lloyds topped the main board
with a 4% leap, while Royal Bank of Scotland added 3%.

Mining heavyweights, which rely on world's top metals
consumer China for a chunk of their profits, were the biggest
sector-wise boost to the main bourse, climbing 2.5% - their most
since early August.

Gains were triggered as hopes of a resolution to a painfully
long trade war returned after U.S. President Donald Trump said
he will meet Chinese Vice Premier Liu He on Friday.

The comments were well received, given they came after
sentiment had turned sour following a report that Beijing has
urged Washington to stop unreasonable pressure on Chinese
companies.

On news-related moves, FTSE 100 component Mondi
reversed earlier losses to close 2% higher after a third-quarter
update, while homewares retailer Dunelm slumped 10% to
the bottom of the midcap index after it flagged a softer market.

Still, reflecting recent worries over trade and Brexit, the
FTSE 100 confirmed a "Death Cross" pattern as its 50-day moving
average (DMA) crossed below the 200 DMA, which is seen a warning
sign that more losses are likely in the near term.

The blue-chip bourse last formed the pattern roughly a year
ago when Brexit negotiations and Italy's budget deficit had hit
risk appetite.

"The ebb and flow of sentiment around U.S., China trade
continues to pull global stock markets from pillar to post," CMC
Markets' Michael Hewson wrote.

(Reporting by Muvija M and Shashwat Awasthi in Bengaluru;
Editing by Bernard Orr and Giles Elgood)

More News
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.